Zurich Hazard Analysis in Biotechnology: Can Risk Management be Improved Using Proactive Communication Strategies?

Nature Biotechnology

Volumn 14, Issue 7, 1996, Pages 894-896

  Jank, Bernhard ^a   Doblhoff Dier, Otto ^a   Haymerle, Harald ^b  

^a UNIVERSITY OF AGRICULTURAL SCIENCES   (Austria)

^b Insurance Company Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE;

BIOTECHNOLOGY; DRUG MANUFACTURE; GENETIC ENGINEERING; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; RISK ASSESSMENT; RISK MANAGEMENT; SHORT SURVEY; VACCINATION;

BIOTECHNOLOGY; PROPORTIONAL HAZARDS MODELS; RISK MANAGEMENT;

EID: 0029937099     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0796-894     Document Type: Article

References (6)

1. Collins, C.H. 1992. Safety in microbiology. An overview, pp.1-5 in Safety in Industrial Microbiology and Biotechnology. Collins, C.H. and Beale, A.J. (eds). Butterworth-Heinemann, Oxford.
2. Frommer, W. and the EFB Working Party. Safety in Biotechnology. 1989. Appl. Microbiol. Biotechnol. 30:541-552.
3. Lelieveld, H.L.M. and the EFB Working Party Safety in biotechnology. 1995. Appl. Microbiol. Biotechnol. 43:389-393.
4. Zurich Insurance Group. 1987. Zurich hazard analysis: A brief introduction to the Zurich method of hazard analysis. Zurich Insurance Company, Zurich.
5. Centers for Disease Control and Prevention (CDC) and National Institutes of Health (NIH). 1993. Biosafety in microbiological and biomedical laboratories, 3rd Ed. US Government Printing Office, Washington, DC.
6. Zurich Insurance Group. 1991. Zurich hazard analysis: ZHA-PC user guide. Zurich Insurance Company, Zurich.